Marker Therapeutics, Inc. — Director's Dealing 2018

Mar 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2018-02-28

Reporting Person: Silverman Joshua (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-28	Common Stock	J	153333	—	Acquired	153333	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-28	Series A Warrants	$1.20	J	41667	Acquired	2020-01-16	Common Stock (41667)	Indirect
2018-02-28	Series C Warrants	$6.00	J	44000	Acquired	2020-01-16	Common Stock (44000)	Indirect
2018-02-28	Series D Warrants	$9.00	J	41667	Acquired	2020-01-16	Common Stock (41667)	Indirect
2018-02-28	Series E Warrants	$4.50	J	10574	Acquired	2020-10-08	Common Stock (10574)	Indirect
2018-02-28	Series E-1 Warrants	$15.00	J	31093	Acquired	2020-10-08	Common Stock (31093)	Indirect
2018-02-28	Series F Warrants	$7.20	J	49167	Acquired	2021-08-11	Common Stock (49167)	Indirect

Footnotes

F1: Securities received from pro rata distribution in connection with the dissolution of American Capital Management LLC, of which the reporting person was a non-managing member.